atezolizumab

Overview

Atezolizumab is a humanized monoclonal antibody that targets Programmed Death-Ligand 1 (PD-L1), a key immune checkpoint molecule expressed on tumor cells and tumor-infiltrating immune cells. By blocking the PD-1/PD-L1 interaction, atezolizumab prevents tumors from evading immune surveillance, thereby restoring the cytotoxic activity of T cells against cancer. Unlike antibodies targeting PD-1 directly (such as nivolumab), atezolizumab binds the ligand itself, potentially preserving PD-1 interactions with PD-L2 and maintaining a broader immune balance. Originally developed by Genentech/Roche, atezolizumab has received regulatory approval for multiple indications including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), hepatocellular carcinoma (HCC), and bladder cancer, positioning it as one of the most broadly applied anti-PD-L1 agents in oncology.

Mechanistically, atezolizumab engages the innate and adaptive immune systems by unleashing tumor-infiltrating lymphocytes that have been suppressed by PD-L1 signaling. The drug has been extensively studied both as a monotherapy and in combination regimens — most notably with bevacizumab, an anti-VEGF antibody — where the dual blockade of immune checkpoint suppression and tumor angiogenesis is hypothesized to yield synergistic antitumor efficacy. The interplay between growth factors such as VEGF and TGF-β1, interleukin-6, and PD-L1 expression underscores the rationale for these combination strategies and continues to drive a broad and growing research program.

Focus of Latest Publications

Recent publications across multiple cancer types characterize atezolizumab's established role and emerging applications in combination immunotherapy. In unresectable hepatocellular carcinoma, atezolizumab plus bevacizumab has consolidated as standard first-line therapy, with contemporary research documenting real-world diagnostic pathways, treatment outcomes in patients ineligible for locoregional therapy, and clinicopathologic determinants of long-term survival. Investigations compared second-line therapeutic options following atezolizumab plus bevacizumab progression, including durvalumab plus tremelimumab, lenvatinib, and salvage interventions such as balloon-occluded transarterial chemoembolization for refractory disease. Emerging tools for treatment optimization included response assessment via radiological criteria (RECIST 1.1 versus modified RECIST) and novel biomarkers including real-time immune cell activity monitoring to predict treatment response and inform early clinical decisions.

Atezolizumab plus bevacizumab demonstrated manageable tolerability even in patients with advanced HCC proceeding to liver transplantation, achieving one-year post-transplant survival of 77% and HCC recurrence in only one of 15 transplanted patients. Extrahepatic metastatic disease patterns were identified as an independent prognostic factor for survival outcomes in this population. Dose optimization studies evaluated low-dose bevacizumab co-administration to reduce toxicity while maintaining efficacy.

In non-small cell lung cancer, atezolizumab showed activity in both the resectable neoadjuvant and advanced settings. Neoadjuvant atezolizumab combined with carboplatin and nab-paclitaxel achieved major pathologic response in 45% of patients (25% complete response), enabling safe complete surgical resection. Long-term follow-up data from the APPLE trial characterized outcomes with atezolizumab combined with carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous NSCLC. A subcutaneous formulation of atezolizumab demonstrated non-inferior pharmacokinetic exposure and bioavailability to intravenous administration, with superior patient preference and substantially reduced treatment burden, supporting feasibility in resource-constrained settings.

Atezolizumab demonstrated clinical activity in less common malignancies. In alveolar soft part sarcoma, monotherapy achieved an objective response rate of 35.8% with median response duration of 37.0 months; responses were enriched in ASPSCR1::TFE3 type 1 tumors (43.9% ORR) versus type 2 (0% ORR). For follicular lymphoma, atezolizumab combined with obinutuzumab and PET-adapted ultra-low–dose radiotherapy yielded 93% complete response rate and 80% three-year progression-free survival. In stage III mismatch repair–deficient colon cancer, adjuvant atezolizumab plus mFOLFOX6 improved three-year disease-free survival to 86.3% versus 76.2% with chemotherapy alone (hazard ratio 0.50; p<0.001). Preliminary investigations in PD-L1–positive metastatic triple-negative breast cancer examined sequential therapy with induction bevacizumab and paclitaxel followed by atezolizumab and nab-paclitaxel to overcome vascular endothelial growth factor–associated resistance. Rare immune-related adverse events including vitamin B12–deficient pernicious anemia warrant clinical monitoring during extended treatment courses.

Key Publications

• NEWJul Balloon-occluded Alternative Infusion of Fragmented Gelatin Particles of TACE for Hepatocellular Carcinoma Refractory to Atezolizumab-Bevacizumab. (Anticancer research, 2026, PMID 42373279): "This study aimed to verify the efficacy and safety of balloon-occluded alternative infusion of cisplatin solution and gelatin particles of transarterial chemoembolization (BOAI-TACE) for hepatocellular carcinoma (HCC) refractory or intolerant to atezolizumab plus bevacizumab combination therapy."
• NEWJun Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort. (JHEP reports : innovation in hepatology, 2026, PMID 42276189): "This study aimed to describe access to and outcomes of second-line (2L) treatments following atezolizumab-bevacizumab (AB) compared with sorafenib (Sor),"
• May Focused acoustic vortex-mediated targeted aggregation of engineered bacteria for in situ antibody production to enhance immunotherapy. (Acta biomaterialia, 2026, PMID 42217659): "Engineered bacteria were conjugated with multifunctional nanoparticles combining chemotherapy, sonodynamic therapy, and plasmid-encoded anti-PD-L1, forming microbots capable of ultrasound-mediated aggregation and deep tumor penetration."
• May Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis. (Oncology, 2026, PMID 42213615): "We examined diagnostic pathways and outcomes of first-line atezolizumab plus bevacizumab (Atz+Bev), with a focus on de novo LRT-ineligible HCC."
• May Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies. (Lung cancer (Amsterdam, Netherlands), 2026, PMID 42214243): "Subcutaneous (SC) and intravenous (IV) atezolizumab is approved for the treatment of several solid tumors."
• Jun Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma-Data From the Multinational LITCHI Registry. (Liver international : official journal of the International Association for the Study of the Liver, 2026, PMID 42156355): "Among 18 patients who underwent LTx following ICI, 15 were treated with atezolizumab plus bevacizumab."
• May Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer. (Lung cancer (Amsterdam, Netherlands), 2026, PMID 42127535): "The phase III APPLE trial evaluated the efficacy of adding bevacizumab to atezolizumab with carboplatin plus pemetrexed (APP) for individuals with advanced nonsquamous non-small cell lung cancer (NSCLC)."
• May Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10). (BMJ open, 2026, PMID 42128502): "Addition of bevacizumab and paclitaxel as induction therapy prior to standard atezolizumab and nab-paclitaxel in patients with programmed death-ligand 1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) may help to overcome vascular endothelial growth factor-associated resistance mechanisms that limit the immune-mediated antitumour efficacy of atezolizumab and nab-paclitaxel."
• May A Case of Pernicious Anemia Induced by Atezolizumab in Hepatocellular Carcinoma and Renal Cell Carcinoma. (The American journal of case reports, 2026, PMID 42106905): "We found that PA was associated with parietal cell antibody production triggered by atezolizumab, in which the removal of immune checkpoint brakes by atezolizumab may reveal this pathogenesis."
• May Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. (PloS one, 2026, PMID 42096473): "The optimal second-line therapy following first-line atezolizumab plus bevacizumab remains unascertained."